Pfizer, Teva reach deal to allow generic Viagra

December 17, 2013 by The Associated Press

Pfizer says it reached a settlement with Teva Pharmaceuticals that allows the generic drugmaker to launch a copycat version of its popular erectile dysfunction drug Viagra in 2017.

Pfizer says Teva will pay an undisclosed royalty for a license to produce a of Viagra, one of New York-based Pfizer's best-selling drugs. Viagra generated about $1.14 billion in U.S. sales last year.

Pfizer's patent protecting Viagra from generic competition expires in April 2020, but Teva will be allowed to launch its generic version Dec. 11, 2017.

Pfizer Inc. had sued Teva in 2010 over the Israeli drugmaker's plans to introduce a generic version of Viagra.

The patent protecting another , Eli Lilly and Co.'s Cialis, also expires in 2017.

Explore further: Canada high court voids Pfizer's Viagra patent

Related Stories

Canada high court voids Pfizer's Viagra patent

November 8, 2012

Canada's top court on Thursday stripped Pfizer of its patent for Viagra, saying the pharmaceutical giant failed in the patent to identify the active compound in the drug.

FDA approves first generic versions of Cymbalta

December 11, 2013

The Food and Drug Administration says it has approved the first generic versions of the blockbuster antidepressant drug Cymbalta, offering lower-cost access to one of the most widely prescribed treatments for depression, ...

S. Korea to approve Viagra generics

March 14, 2012

Three South Korean pharmaceutical firms will soon be allowed to produce generic versions of the anti-impotence drug Viagra despite a row over patents, officials said Wednesday.

Pfizer painkiller gets longer patent protection (Update)

March 5, 2013

Drugmaker Pfizer Inc. said Tuesday that a new patent on one of its top drugs, anti-inflammatory painkiller Celebrex, extends its U.S. patent protection by 18 months, potentially bringing the company a few billion dollars ...

Recommended for you

Researchers identify source of opioids' side effects

January 17, 2017

A commercially available drug may help drastically reduce two side effects of opioid painkillers—a growing tolerance and a paradoxical increased sensitivity to pain—without affecting the drugs' ability to reduce pain, ...

CVS generic competitor to EpiPen, sold at a 6th the price

January 12, 2017

CVS is now selling a rival, generic version of Mylan's EpiPen at about a sixth of its price, just months after the maker of the life-saving allergy treatment was eviscerated before Congress because of its soaring cost to ...

Many misuse OTC sleep aids: survey

December 29, 2016

(HealthDay)—People struggling with insomnia often turn to non-prescription sleep remedies that may be habit-forming and are only intended for short-term use, according to a new Consumer Reports survey.

The pill won't kill your sexual desire, researchers say

December 15, 2016

Taking the pill doesn't lower your sexual desire, contrary to popular belief, according to research published in the Journal of Sexual Medicine. The authors of the research, from the University of Kentucky and Indiana University ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.